AI Pharmaceutical Company
Total Trials
5
As Lead Sponsor
4
As Collaborator
1
Total Enrollment
679
NCT03527472
Memantine for the Treatment of Cognitive Impairment in Systemic Lupus Erythematosus
Phase: Phase 2
Role: Collaborator
Start: Aug 23, 2018
Completion: Dec 31, 2025
NCT04561180
Study to Evaluate the Efficacy and Safety of EG-009A Compared to DEX in Patients With COVID-19 Pneumonia
Role: Lead Sponsor
Start: Mar 4, 2022
Completion: May 1, 2023
NCT05170048
Study to Evaluate Safety and Efficacy of EG-301 in Patients with Nonfocal Geographic Atrophy Secondary to DAMD
Start: Jun 30, 2025
Completion: Jun 30, 2026
NCT05106127
Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem
Start: Aug 31, 2025
Completion: Mar 31, 2026
NCT05077215
Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer
Phase: Phase 3
Start: Dec 31, 2025
Completion: Dec 31, 2026
Loading map...